RESUMEN
Up to 100,000 total knee arthroplasties are performed annually in Germany resulting in an increasing number of revision operations. Different underlying causes might preclude the reimplantation of an endoprosthesis, and knee arthrodesis represents the alternative of first choice to above-knee amputation. The most common indications for arthrodesis are the infected knee arthroplasty with defects of the extensor mechanism, soft tissue and bone defects, and persisting infection. Several procedures of arthrodesis have been introduced and should be well adapted to the individual situation of the patient. The results--especially related to quality of life--are encouraging and should facilitate the demanding decision if a total joint reimplantation is not reasonable.
Asunto(s)
Artrodesis/métodos , Artroplastia de Reemplazo de Rodilla/efectos adversos , Inestabilidad de la Articulación/etiología , Inestabilidad de la Articulación/prevención & control , Prótesis de la Rodilla/efectos adversos , Infecciones Relacionadas con Prótesis/cirugía , Reimplantación/métodos , Terapia Recuperativa/métodos , Humanos , Guías de Práctica Clínica como Asunto , Pautas de la Práctica en Medicina , Pronóstico , Infecciones Relacionadas con Prótesis/etiología , Resultado del TratamientoRESUMEN
The objective of this study was to compare efficacy and safety of continuous versus intermittent oral dosing of ibandronate. Two hundred forty women aged 55-75 years with postmenopausal osteoporosis were randomized to active treatment or placebo. Similar total doses of ibandronate were provided by treatment regimens with either continuous 2.5 mg of ibandronate daily (n = 81) or intermittent 20 mg of ibandronate every other day for the first 24 days, followed by 9 weeks without active drug (n = 78). The placebo group (total, n = 81) was crossed over after 12 months to receive either continuous (n = 37) or intermittent ibandronate (n = 35). By 24 months, bone mineral density (BMD) had increased significantly relative to baseline in both active treatment groups. The continuous and intermittent groups showed statistically equivalent increases in lumbar spine BMD of +5.64% (+/-0.53) and +5.54% (+/-0.53) and in total hip of +3.35% (+/-0.40) and +3.41% (+/-0.40), respectively (per protocol population). Biochemical markers of bone turnover decreased significantly in both treatment groups. The level of marker suppression was similar, although the intermittent group displayed, as expected, more fluctuation over the treatment period. The frequency of adverse events was similar in the treatment groups. In conclusion, the intermittent and continuous regimens showed equivalent changes in BMD and bone turnover. These results confirm previous preclinical findings indicating that the efficacy of ibandronate depends on the total oral dose given rather than on the dosing schedule. This supports development of new flexible dosing regimens targeted to minimize the frequency of dosing, which are expected to improve convenience and lead to enhanced long-term patient compliance.
Asunto(s)
Resorción Ósea , Difosfonatos/uso terapéutico , Osteoporosis Posmenopáusica/tratamiento farmacológico , Administración Oral , Anciano , Biomarcadores/sangre , Biomarcadores/orina , Densidad Ósea/efectos de los fármacos , Seguridad de Productos para el Consumidor , Estudios Cruzados , Difosfonatos/administración & dosificación , Difosfonatos/efectos adversos , Esquema de Medicación , Tolerancia a Medicamentos , Femenino , Cadera/fisiopatología , Humanos , Ácido Ibandrónico , Vértebras Lumbares/efectos de los fármacos , Vértebras Lumbares/fisiopatología , Persona de Mediana Edad , Osteoporosis Posmenopáusica/sangre , Osteoporosis Posmenopáusica/fisiopatología , Osteoporosis Posmenopáusica/orinaRESUMEN
Elevated concentrations of lipoprotein(a) [Lp(a)] have been shown to be an independent risk factor for atherosclerotic disease. Physical activity and physical fitness have been shown to improve lipoprotein metabolism and reduce the risk of coronary artery disease. Studies on the influence of physical activity and physical fitness on Lp(a) levels including a large number of endurance as well as power athletes have not been performed before. Therefore, we determined parameters of physical fitness (maximal oxygen consumption), physical activity, and lipoproteins in 105 endurance athletes, 57 power athletes, and 87 sedentary young men. As expected, we found that endurance athletes with a good physical fitness had significantly higher concentrations of high-density lipoprotein cholesterol than power athletes and sedentary controls. Regarding mean Lp(a) levels (rocket immunoelectrophoresis), however, there were no significant differences between endurance athletes, power athletes, and sedentary controls. Even when including only those with Lp(a) values > 10 mg.dl-1, no differences were observed between the groups. These findings indicate that intensive training over years and good aerobic fitness improve the ratio of low-density lipoprotein to high-density lipoprotein cholesterol but have no or only minor effects on Lp(a) concentrations.